Monitoring abacavir bioactivation in humans: Screening for an aldehyde metabolite
Graphical abstract
Highlights
► We identified abacavir–protein adducts in the hemoglobin of HIV-infected patients. ► Abacavir–protein adducts might be used as biomarkers of ABC-induced toxicity. ► We present the first evidence of abacavir–protein adduct formation in humans. ► The data provide clues to the mechanisms underlying abacavir adverse reactions.
Introduction
The anti-HIV drug abacavir (ABC; Scheme 1) is associated with hypersensitivity reactions (HSRs), characterized by systemic symptoms that include fever, rash, nausea, vomiting, abdominal pain, lethargy and malaise. This allergenic response occurs generally within the first 6 weeks of treatment and has been linked to HLA class I allele HLA-B*57:01 (Nolan, 2009). In addition, long-term abacavir exposure has been associated with an increased risk of myocardial infarction (Costagliola et al., 2010, Islam et al., 2012) that prompted the FDA to issue an alert for heart attack risk in March 2011 (FDA, 2011). The potential for cardiotoxicity raises further concerns about chronic use of the drug and calls for urgent and accurate risk/benefit estimations. Toward this goal, both a thorough understanding of the mechanisms of abacavir-induced toxicity and the development of reliable toxicity biomarkers are required.
Four different models/hypotheses have been considered to explain the mechanism of the immune-mediated adverse reactions induced by abacavir: (1) the hapten/prohapten hypothesis (Uetrecht, 2007); (2) the pharmacological interaction with immune receptors, the p–i hypothesis (Pichler et al., 2006); (3) the danger model, which is complementary of the hapten hypothesis, adding a secondary signal (e.g. an infection) (Pirmohamed et al., 2002), and (4) the altered peptide model (Illing et al., 2012, Mallal and Phillips, 2012, Norcross et al., 2012, Ostrov et al., 2012). The hapten hypothesis considers that drugs or their metabolites are too small to be immunogenic. Instead, they can bind irreversibly to proteins, generating covalent adducts, which act as antigens (Uetrecht, 2007). The p–i hypothesis advocates a non-covalent interaction between the drug and the HLA protein, implying the formation of neo-antigen determinants, without the involvement of the proteasome. The most recent evidence that HLA-B*5701 is able to lodge abacavir led to the proposal of the altered peptide model, suggesting that binding of the parent drug per se can influence the repertoire of self-peptide ligands to be presented and trigger abacavir-induced HSR (Chessman et al., 2008, Yang et al., 2009, Bharadwaj et al., 2012, Illing et al., 2012, Mallal and Phillips, 2012, Ostrov et al., 2012).
Regardless of the specific mechanism of abacavir-induced HSR, it is noteworthy that the immunogenic effects of the drug are dose-dependent (Adam et al., 2012, Norcross et al., 2012, Ostrov et al., 2012). This correlation suggests that abacavir metabolism could be involved. Therefore, a clarification of the drug's metabolic pathways is essential to fully comprehend the mechanisms of abacavir toxicity.
The molecular mechanisms of abacavir-induced cardiotoxicity are even less understood. Although an immune-mediated response can be envisioned, metabolic activation of abacavir to aldehyde intermediates might play a significant role in this context. This hypothesis is consistent with the fact that several aldehydes have been associated with the inception of cardiovascular pathologies. For instance, acetaldehyde, the primary ethanol metabolite, is thought to be involved in the onset of alcoholic cardiomyopathy (Guo and Ren, 2010a). The report of an exacerbated ethanol-induced myocardial contractile dysfunction following acute ethanol exposure, in a murine model with cardiac-specific overexpression of alcohol dehydrogenase (ADH) (Guo and Ren, 2010b), suggests that heart metabolism to aldehydes, and subsequent site-specific protein modification, may underlie xenobiotic-induced cardiotoxicity. Similarly, exposure to the highly reactive α, β-unsaturated aldehyde acrolein, an endogenous product of lipid peroxidation and ubiquitous environmental pollutant, has been shown to cause myocardial dysfunction (Luo et al., 2007).
Abacavir is a guanosine analog, which is converted intracellularly to the pharmacologically active metabolite, carbovir triphosphate (CBV-TP), via stepwise anabolism. Abacavir is initially phosphorylated to abacavir monophosphate (ABC-MP) by adenosine phosphotransferase, followed by deamination via a cytosolic enzyme to form carbovir monophosphate (CBV-MP). Then two subsequent phosphorylations occur, to the diphosphate by guanylate kinase, and finally to carbovir triphosphate (CBV-TP) by nucleoside diphosphate kinase (Scheme 1). The active metabolite competes with endogenous 2′-deoxyguanosine triphosphate for the nucleic acid chain and, upon incorporation, terminates the DNA chain extension (Faletto et al., 1997, Hervey and Perry, 2000). Concurrently with this activation process abacavir is extensively metabolized by the liver. Primary abacavir metabolism pathways comprise Phase II glucuronidation, mediated by uridine diphosphate glucuronyltransferase and yielding an inactive glucuronide metabolite (ABC-glucuronide), and Phase I oxidation, mediated by ADH and yielding a carboxylate (ABC-carboxylate). These metabolites are excreted primarily in the urine, where in combination they account for 66% of the dose; an additional 15% of the dose is converted into a number of minor metabolites (McDowell et al., 1999), but structural considerations suggest that none of those identified to date are potentially reactive intermediates. By contrast, abacavir metabolism to the carboxylate involves a two-step oxidation process, via a reactive aldehyde intermediate (Walsh et al., 2002). The formation of isomers of both the acid metabolite and the parent drug through ADH metabolism led Walsh et al. (2002) to propose a metabolic pathway involving double bond migration and epimerization processes upon formation of two putative aldehyde intermediates: an unconjugated aldehyde and a conjugated aldehyde (Scheme 1).
We have demonstrated previously that the conjugated aldehyde is capable of reacting with proteins in vitro (Charneira et al., 2011) and in rats (Charneira et al., 2012) but, so far, this metabolite has eluded detection in humans. The present work was aimed at identifying abacavir–hemoglobin adducts in HIV-infected patients as biomarkers of abacavir bioactivation to an aldehyde metabolite.
Section snippets
Chemicals and standards
All reagents were purchased from Sigma–Aldrich Química S.A. (Madrid, Spain) and used as received. The abacavir–valine Edman adduct standard was synthesized and characterized as described in Charneira et al. (2011).
Study design
The protocol received prior approval from the Ethics Committee of Centro Hospitalar de Lisboa Central, EPE and patients gave their written informed consent. All eligible patients were adults with documented HIV-infection who had received continuous treatment with abacavir-based
Results
To obtain evidence for abacavir bioactivation to a reactive aldehyde metabolite in humans, the presence of abacavir adducts with the N-terminal valine of hemoglobin was investigated in ten HIV-infected patients (5 men and 5 women; 34–83 years old; 560 ± 280 CD4+ cells mm−3; Table 1).
The N-alkyl Edman procedure was used for specific detachment of adducts from hemoglobin. LC–ESI–MS/MS analysis of the MS3 transition of the protonated molecule [m/z 503 → 313 → 235] (Fig. 1A) allowed the unequivocal
Discussion
The present work was aimed at identifying abacavir–hemoglobin adducts in HIV-infected patients as biomarkers of abacavir bioactivation to an aldehyde metabolite. Aldehydes are often implicated in hypersensitivity conditions due to their ability to modify proteins (O’Brien et al., 2005); this, and the fact that ADH is present in epithelial tissues, including the skin (Lockley et al., 2005), strongly supports the involvement of aldehyde metabolites in abacavir-induced skin toxicity. Likewise, the
Conclusion
Taken together, the results reported herein demonstrate that the search for causal relationships between the formation of abacavir-derived protein adducts and the occurrence of abacavir-induced toxic events in human patients is worth pursuing. Moreover, the adduct characterization methodology described in the present study is simple, sensitive, accurate, reliable, and applicable to high throughput analyses, as required for testing clinical samples. As such, it is of significant worth for
Role of the funding source
This work was supported by Fundação para a Ciência e a Tecnologia (FCT, Portugal), through research grants (PTDC/SAU-TOX/111663/2009 and PTDC/QUI-QUI/113910/2009), and pluriannual funds to Centro de Química Estrutural (PEst-OE/QUI/UI0100/2011).
Conflict of interest statements
The authors declare that there are no conflicts of interest.
Acknowledgement
Thanks are due to the Portuguese MS Network (IST-UTL Center).
References (34)
- et al.
Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity
Immunity
(2008) - et al.
Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality
Journal of Allergy and Clinical Immunology
(2012) - et al.
Pharmacological interaction of drugs with immune receptors: the p–i concept
Allergology International
(2006) - et al.
The danger hypothesis—potential role in idiosyncratic drug reactions
Toxicology
(2002) - et al.
Protein adducts: quantitative and qualitative aspects of their formation, analysis and applications
Journal of Chromatography B
(2002) - et al.
The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes
Chemico-Biological Interactions
(2002) - et al.
Avidity determines T-cell reactivity in abacavir hypersensitivity
European Journal of Immunology
(2012) - et al.
Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex
Annual Review of Pharmacology and Toxicology
(2012) - et al.
Reactive aldehyde metabolites from the anti-HIV drug abacavir: amino acid adducts as possible factors in abacavir toxicity
Chemical Research in Toxicology
(2011) - et al.
N-terminal valine adduct from the anti-HIV drug abacavir in rat haemoglobin as evidence for abacavir metabolism to a reactive aldehyde in vivo
British Journal of Pharmacology
(2012)
Abacavir and cardiovascular risk: reviewing the evidence
Current HIV/AIDS Reports
HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity
British Medical Journal
Glutathione depletion in HIV-infected patients: role of cysteine deficiency and effect of oral N-acetylcysteine
AIDS
Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89
Antimicrobial Agents and Chemotherapy
Alcohol and acetaldehyde in public health: from marvel to menace
International Journal of Environmental Research and Public Health
Alcohol dehydrogenase accentuates ethanol-induced myocardial dysfunction and mitochondrial damage in mice: role of mitochondrial death pathway
PLoS One
Cited by (22)
Lead to hit ruthenium-cyclopentadienyl anticancer compounds: Cytotoxicity against breast cancer cells, metabolic stability and metabolite profiling
2024, Journal of Inorganic BiochemistryAbacavir-induced liver toxicity
2016, Brazilian Journal of Infectious DiseasesBioactivation to an aldehyde metabolite-Possible role in the onset of toxicity induced by the anti-HIV drug abacavir
2014, Toxicology LettersCitation Excerpt :These adducts are processed by antigen presenting cells into peptide fragments which, associated with the MHC class I, interact with T-cell receptors (TCR) (Uetrecht, 2007; Bharadwaj et al., 2010; Park et al., 2011; Pichler et al., 2011). Whereas an HLA-specific ABC-haptenated peptide has yet to be detected, the identification by mass spectrometry methods of ABC-derived N-terminal valine adducts in the hemoglobin of HIV-infected patients on ABC regimens (Grilo et al., 2013), demonstrated unequivocally that ABC is bioactivated to an aldehyde metabolite in vivo, and that this metabolite exists long enough in humans to undergo protein haptenation with blood proteins. It is well recognized that ABC-specific T cells are not activated by antigen-presenting cells expressing the closely related allotypes HLA-B*57:03, HLA-B*57:02, and HLA-B*58:01, which suggests that ABC-HLA-B*57:01 specificity is related to the F-pocket architecture.
Formation of potentially toxic metabolites of drugs in reactions catalyzed by human drug-metabolizing enzymes
2024, Archives of ToxicologyAmino Acid and Biogenic Amine Adductions Derived from Reactive Metabolites
2021, Current Drug Metabolism